Form 4: Apogee Therapeutics CFO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics CFO Jane Henderson sold 1,000 shares of common stock for $60 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc. (APGE), reported a transaction involving the company's common stock.
• On November 11, 2025, Ms. Henderson disposed of 1,000 shares of common stock.
• The shares were sold at a price of $60 per share.
• Following this transaction, Ms. Henderson beneficially owns 199,871 shares of Apogee Therapeutics common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on September 27, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction executed under a pre-arranged 10b5-1 trading plan, which typically indicates a scheduled personal financial event rather than a reaction to new material information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide broader industry context or trends. It reflects a pre-scheduled sale by a corporate officer, common across various industries for personal financial planning.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by a CFO under a 10b5-1 plan is generally not considered to have a significant impact on shareholder sentiment or the company's valuation.

Key Dates

Recommendation

The sale of 1,000 shares by the CFO was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than a discretionary one based on new material non-public information. This type of transaction is generally considered neutral and does not typically signal a change in the company's fundamental outlook or warrant an immediate change in investment recommendation.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, CFO, Jane Henderson, 10b5-1 Plan